Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

98 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hammertoe deformity is the most common deformity of the lesser toes. It primarily comprises flexion deformity of the proximal interphalangeal (PIP) joint of the toe, with hyperextension of the metatarsophalangeal (MTP).

Etiologies of hammertoe deformity include a foot in which the second ray is longer than the first, MTP synovitis and instability, inflammatory arthropathies, neuromuscular conditions, and ill-fitting shoe wear. When a foot's second ray is longer than the first and shoe wear does not fit correctly, flexion of the PIP joint occurs to accommodate the shoe. This length difference also causes MTP synovitis to develop from overuse of the second MTP joint. Attenuation of the collateral ligaments and plantar plate result, and the MTP joint hyperextends and may even progress to dorsal subluxation or dislocation (see image below). Rheumatoid arthritis causes hammertoe deformity by progressive MTP joint destruction, leading to MTP joint subluxation and dislocation.

With all 3 of these etiologies, the extensor digitorum longus (EDL) tendon gradually loses mechanical advantage at the PIP joint, as does the flexor digitorum longus (FDL) tendon at the MTP joint. The intrinsic muscles fire and sublux dorsally, as the MTP hyperextends. They now extend the MTP joint and flex the PIP joint, as opposed to their usual functions of flexing the MTP joint and extending the PIP joint.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can Hypermobility of First Ray Affect Surgical Treatment of Hallux Valgus

NCT05051709

Hallux Valgus

UNKNOWN NA

Treatment Effects on Gait in Hammertoe Patients

NCT07166016

Hammertoe

RECRUITING NA

Surgical Treatment for Hallux Rigidus

NCT01048450

Hallux Limitus Hallux Rigidus

COMPLETED NA

Intramedullary Resorbable Fixation System Versus K-wire for the Treatment of Lesser Toe Deformities

NCT04610437

Hammer Toe Surgery Deformity of Toe +1 more

COMPLETED NA

A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes

NCT01927952

Acquired Deformities of Toe

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Device Description:

Nextra implant is an anatomical 2-piece designed implant with 10° angulation with a locking fusion mechanism. The self-centering, metaphysis screw design allows a stable and secure relationship of the proximal and middle phalanges. The compression with progressive tightening approximates the bone surfaces for a controlled fusion.

Pre-clinical Data:

The Nextra Implant has been used to create fusions between the proximal and middle phalanges of the 2nd, 3rd. or 4th. toe.

Clinical Experience:

The NextraTM Implant has been used in humans as an implant to reduce hammertoe and contracture deformities.

2\. STUDY OBJECTIVES: The primary objective is to evaluate the post-market safety and performance of NextraTM in the reduction of post-operative pain symptoms in hammertoes and demonstrate the efficacy of the implant to securely stabilize bone surfaces to be fused as to be compared to K-wire fixation.

3\. STUDY DESIGN: General Design: Preoperative and post-operative factors will be assessed in the evaluation of efficacy and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Foot Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nextra fusion

group that has the nextra device

No interventions assigned to this group

k wire fixation

control group fixated with k wire

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pain in the toe reported for greater than 3 months.
* Subjects are males or females,
* Diagnosed with a hammertoe, contracture of the IPJ, or other condition,
* Requiring digital proximal inter-phalangeal joint fusion of the 2nd, 3rd or 4th toe.
* Unilateral deformity of a single digit (2nd, 3rd or 4th)
* Subjects will sign an informed consent.
* Subjects are willing to return for follow-up visits and fill out Quality of Life questionnaires

Exclusion Criteria

* Previous digital fusion surgery Previous PIPJ arthroplasty
* Bilateral surgery Hallux valgus creating a crossover toe with 2nd toe
* Inability to walk without an assistive device
* Infection Rheumatic joint disease
* Peripheral vascular disease with sensory loss to the toe
* Pregnant
* Osteoporosis
* Obvious loss of digital bone density Severe respiratory disease
* Open wounds
* Patients presently taking Gabapentin (Neurontin), Pregabalin (Lyrica), etc. drugs for neuropathic pain
* Diabetics
* Narcotic dependence
* Inability to consent to the research
* Concurrent involvement in another clinical trial
* Known allergy to the device components
* Known metabolic bone disease
* Renal disease (CRI, CRF)
* Skeletal muscle spasticity or paralysis

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes